CancerLinQ LLC, Alexandria, Va, and the American College of Medical Genetics and Genomics (ACMG) have entered into a programmatic collaboration.
CancerLinQ is the health information technology platform of the American Society of Clinical Oncology (ASCO), designed by oncologists for oncologists to leverage the power of big data to improve the quality of care for patients with cancer.
Kevin Fitzpatrick, CancerLinQ.
“The field of medical genetics and genomic medicine is on the leading edge in preventing, diagnosing, and treating diseases, including cancer,” says Kevin Fitzpatrick, chief executive of CancerLinQ. “Having the benefit of working with leaders in this pioneering field offers great possibilities for CancerLinQ as we work to enhance the quality and value of oncology care.”
ACMG is an interdisciplinary professional membership organization that represents the interests of the entire medical genetics team, including clinical geneticists, clinical laboratory geneticists, and genetic counselors. The organization is committed to developing and sustaining genetic and genomic initiatives in clinical and laboratory practice, education, and advocacy.
Louanne Hudgins, MD, FACMG, American College of Medical Genetics and Genomics.
“Many ACMG members are integrally involved in assisting patients and their families in diagnosing hereditary cancer syndromes,” says Louanne Hudgins, MD, FACMG, president of ACMG. “We look forward to what we believe will be a mutually beneficial collaboration with CancerLinQ.”
Peter J. Hulick, MD, MMSc, FACMG, medical director of the center for personalized medicine and center for medical genetics at NorthShore University HealthSystem and clinical assistant professor of human genetics at the University of Chicago Pritzker School of Medicine, will serve as ACMG’s representative on the CancerLinQ oncology leadership council, the strategic advisory body comprising all official partner organizations, which guides the growth and direction of CancerLinQ. ACMG will have the ability to access CancerLinQ Discovery, which provides access to curated sets of statistically deidentified clinical data from the CancerLinQ platform, for the association’s internal analysis of the current, real-world state of cancer care.
The collaboration with ACMG is one of many that CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has entered into with a coalition of partners and thought leaders, including government agencies, medical specialty societies, and life sciences companies. Since 2016, the American Academy of Physician Assistants, American Society of Radiation Oncology, Association for Molecular Pathology, Cancer Informatics for Cancer Centers, College of American Pathologists, Drug Information Association, FDA, Hematology/Oncology Pharmacy Association, National Cancer Institute, National Society of Genetic Counselors, Oncology Nursing Society, and Society of Gynecologic Oncology have joined forces with CancerLinQ. Additionally, in November 2016, AstraZeneca became a founding enterprise partner with CancerLinQ Discovery. These partnerships seek to offer the CancerLinQ team guidance and insights that can ultimately contribute to the quality and efficiency of the cancer care delivery system.
